Trump Administration Mulls COVID-19 Vaccine Ban: Report
ByAinvest
Monday, Aug 25, 2025 6:17 pm ET1min read
BNTX--
Dr. Malhotra, a British cardiologist and vocal vaccine critic, told The Daily Beast that members of President Donald Trump's family support Kennedy's position, despite lacking medical or scientific expertise. Malhotra is an adviser to Make America Healthy Again (MAHA) Action, a group aligned with Kennedy's public health agenda [1].
The potential withdrawal of COVID-19 vaccines could have significant implications for the market. Following the report, stocks of vaccine manufacturers, including Pfizer Inc. (NYSE:PFE), BioNTech SE (NASDAQ:BNTX), Moderna Inc. (NASDAQ:MRNA), and Novavax Inc. (NASDAQ:NVAX), began trading lower. Pfizer's stock fell by 2.53%, BioNTech's by 3.31%, Moderna's by 4.48%, and Novavax's by 4.27% [2].
The decision to withdraw the vaccine is reportedly rooted in skepticism about the safety of mRNA vaccines. Central to Kennedy's stance is a 2022 peer-reviewed paper published in the journal Vaccine, which claimed mRNA vaccines were associated with a 16% higher rate of serious adverse events than placebos in clinical trials. However, the study has been widely dismissed by the scientific community due to methodological concerns and claims of bias [1].
The White House has denied these claims. White House spokesperson Kush Desai stated, "The Administration is relying on Gold Standard Science and is committed to radical transparency to make decisions that affect all Americans. Any discussion about HHS policy should be dismissed as baseless speculation unless officially announced" [3].
The potential withdrawal of COVID-19 vaccines comes amid growing skepticism and controversy surrounding the vaccines. In August, a gunman attacked the CDC headquarters in Atlanta, allegedly targeting the agency because of his COVID-19 vaccine beliefs. A group of former CDC employees blamed Kennedy for vilifying the agency's workforce through "his continuous lies about science and vaccine safety, which have fueled a climate of hostility and mistrust" [2].
References:
[1] https://caliber.az/en/post/trump-administration-may-pull-covid-vaccine-within-months
[2] https://www.inkl.com/news/trump-administration-plans-to-pull-covid-19-vaccines-off-market-within-months
[3] https://www.investing.com/news/stock-market-news/moderna-stock-falls-pfizer-dips-on-covid-vaccine-ban-speculation-93CH-4209558
MRNA--
NVAX--
PFE--
The Trump administration is reportedly preparing to withdraw COVID-19 vaccines from the US market within months, according to a Daily Beast report. The move is based on a recommendation from Dr. Aseem Malhotra, a close associate of HHS Secretary Robert F. Kennedy. However, there is no confirmation of the plan from the administration.
The Trump administration is reportedly preparing to withdraw COVID-19 vaccines from the U.S. market within months, according to a Daily Beast report. The move is based on a recommendation from Dr. Aseem Malhotra, a close associate of Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. However, there is no confirmation of the plan from the administration.Dr. Malhotra, a British cardiologist and vocal vaccine critic, told The Daily Beast that members of President Donald Trump's family support Kennedy's position, despite lacking medical or scientific expertise. Malhotra is an adviser to Make America Healthy Again (MAHA) Action, a group aligned with Kennedy's public health agenda [1].
The potential withdrawal of COVID-19 vaccines could have significant implications for the market. Following the report, stocks of vaccine manufacturers, including Pfizer Inc. (NYSE:PFE), BioNTech SE (NASDAQ:BNTX), Moderna Inc. (NASDAQ:MRNA), and Novavax Inc. (NASDAQ:NVAX), began trading lower. Pfizer's stock fell by 2.53%, BioNTech's by 3.31%, Moderna's by 4.48%, and Novavax's by 4.27% [2].
The decision to withdraw the vaccine is reportedly rooted in skepticism about the safety of mRNA vaccines. Central to Kennedy's stance is a 2022 peer-reviewed paper published in the journal Vaccine, which claimed mRNA vaccines were associated with a 16% higher rate of serious adverse events than placebos in clinical trials. However, the study has been widely dismissed by the scientific community due to methodological concerns and claims of bias [1].
The White House has denied these claims. White House spokesperson Kush Desai stated, "The Administration is relying on Gold Standard Science and is committed to radical transparency to make decisions that affect all Americans. Any discussion about HHS policy should be dismissed as baseless speculation unless officially announced" [3].
The potential withdrawal of COVID-19 vaccines comes amid growing skepticism and controversy surrounding the vaccines. In August, a gunman attacked the CDC headquarters in Atlanta, allegedly targeting the agency because of his COVID-19 vaccine beliefs. A group of former CDC employees blamed Kennedy for vilifying the agency's workforce through "his continuous lies about science and vaccine safety, which have fueled a climate of hostility and mistrust" [2].
References:
[1] https://caliber.az/en/post/trump-administration-may-pull-covid-vaccine-within-months
[2] https://www.inkl.com/news/trump-administration-plans-to-pull-covid-19-vaccines-off-market-within-months
[3] https://www.investing.com/news/stock-market-news/moderna-stock-falls-pfizer-dips-on-covid-vaccine-ban-speculation-93CH-4209558

Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue

Comments
No comments yet